[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Oliver Venture [@_OliverVenture](/creator/twitter/_OliverVenture) on x 1328 followers Created: 2025-06-13 11:06:41 UTC $BEAM "Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101" "Rapid and Sustained Increases in Protective HbF: Consistent with data presented at ASH, all patients achieved endogenous HbF levels exceeding XX% and a durable reduction in corresponding HbS below 40%. A pancellular distribution of HbF-expressing cells, with HbF levels per cell above the sickling threshold, was maintained through follow-up. Robust and Sustained Total Hemoglobin (Hb) Levels: Total Hb levels increased rapidly with resolution of anemia in patients after elimination of the transfused blood. Durable Responses Observed:Increases in HbF, decreases in HbS and resolution of anemia were durable for up to XX months. Efficient Cell Collection and Rapid Engraftment: Patients required a median of one mobilization cycle (range: 1-3 cycles). The median time to neutrophil engraftment was XXXX days (range: 12-30), with a median duration of severe neutropenia of XXX days (range: 4-17). The median time to platelet engraftment was XXXX days (range: 11-34). Normalization of Hemolysis Markers and Erythropoietin Levels: Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase and reticulocytes, normalized or improved in all patients following BEAM-101 treatment. Erythropoietin levels also decreased to normal or near normal, indicating significant improvement in oxygen delivery to tissues. Safety Profile Consistent with Busulfan and Autologous Hematopoietic Stem Cell Transplantation (HSCT): The safety profile of BEAM-101 was consistent with busulfan conditioning, autologous HSCT and underlying SCD. The most common treatment-emergent adverse events (TEAEs) were consistent with busulfan conditioning, including stomatitis, febrile neutropenia and anemia. As previously reported, one patient died four months after BEAM-101 infusion due to respiratory failure that was determined by the investigator to be likely related to busulfan conditioning and deemed unrelated to BEAM-101. No VOCs Reported: No patients experienced any investigator-reported VOCs post-engraftment. Improved Red Blood Cell (RBC) Health and Function: Exploratory biomarker assessments of RBC health and function demonstrated improvements compared to baseline across multiple parameters after BEAM-101 treatment, including in multiple RBC sickling kinetic measurements to levels comparable to sickle cell trait, decreased RBC adhesion and percent dense RBCs, along with reduction in systemic inflammation." "Enrollment in the adult and adolescent cohorts of the BEACON trial is complete, and XX patients were dosed with BEAM-101 as of June 13, 2025. Beam expects to dose XX patients by mid-2025 and share additional data from the trial by the end of 2025." XXXXX engagements  **Related Topics** [ash](/topic/ash) [$beam](/topic/$beam) [coins defi](/topic/coins-defi) [coins bsc](/topic/coins-bsc) [coins gaming](/topic/coins-gaming) [beam beam therapeutics inc](/topic/beam-beam-therapeutics-inc) [Post Link](https://x.com/_OliverVenture/status/1933481144106037320)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Oliver Venture @_OliverVenture on x 1328 followers
Created: 2025-06-13 11:06:41 UTC
$BEAM
"Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101"
"Rapid and Sustained Increases in Protective HbF: Consistent with data presented at ASH, all patients achieved endogenous HbF levels exceeding XX% and a durable reduction in corresponding HbS below 40%. A pancellular distribution of HbF-expressing cells, with HbF levels per cell above the sickling threshold, was maintained through follow-up.
Robust and Sustained Total Hemoglobin (Hb) Levels: Total Hb levels increased rapidly with resolution of anemia in patients after elimination of the transfused blood.
Durable Responses Observed:Increases in HbF, decreases in HbS and resolution of anemia were durable for up to XX months.
Efficient Cell Collection and Rapid Engraftment: Patients required a median of one mobilization cycle (range: 1-3 cycles). The median time to neutrophil engraftment was XXXX days (range: 12-30), with a median duration of severe neutropenia of XXX days (range: 4-17). The median time to platelet engraftment was XXXX days (range: 11-34).
Normalization of Hemolysis Markers and Erythropoietin Levels: Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase and reticulocytes, normalized or improved in all patients following BEAM-101 treatment. Erythropoietin levels also decreased to normal or near normal, indicating significant improvement in oxygen delivery to tissues.
Safety Profile Consistent with Busulfan and Autologous Hematopoietic Stem Cell Transplantation (HSCT): The safety profile of BEAM-101 was consistent with busulfan conditioning, autologous HSCT and underlying SCD. The most common treatment-emergent adverse events (TEAEs) were consistent with busulfan conditioning, including stomatitis, febrile neutropenia and anemia. As previously reported, one patient died four months after BEAM-101 infusion due to respiratory failure that was determined by the investigator to be likely related to busulfan conditioning and deemed unrelated to BEAM-101.
No VOCs Reported: No patients experienced any investigator-reported VOCs post-engraftment.
Improved Red Blood Cell (RBC) Health and Function: Exploratory biomarker assessments of RBC health and function demonstrated improvements compared to baseline across multiple parameters after BEAM-101 treatment, including in multiple RBC sickling kinetic measurements to levels comparable to sickle cell trait, decreased RBC adhesion and percent dense RBCs, along with reduction in systemic inflammation."
"Enrollment in the adult and adolescent cohorts of the BEACON trial is complete, and XX patients were dosed with BEAM-101 as of June 13, 2025. Beam expects to dose XX patients by mid-2025 and share additional data from the trial by the end of 2025."
XXXXX engagements
Related Topics ash $beam coins defi coins bsc coins gaming beam beam therapeutics inc